This reduces the risk of hypoglycemia compared to some other diabetes medications
In the future, patients using GLP-1 patches with GLP-1 or GIP/GLP-1 molecules may experience the side effects of GLP-1 agonist drugs, such as constipation, diarrhea, vomiting, abdominal pain, gallbladder disease, pancreatitis, kidney injury, and hypoglycemia
Chin J Hospital Pharm
Notably, Novo Nordisk, a Danish pharmaceutical company, has recently developed the monoclonal antibody [MAb]3F52, which can specifically bind to the extracellular domain (ECD) Fab region of GLP-1R, and enabled the selective detection of GLP-1R in C57BL mice (43)
Important Current Status Update : On March 19, 2025, the FDA ended enforcement discretion for compounded tirzepatide
[DOI] [Google Scholar] 239.Slingu M